Universal Beteiligungs und Servicegesellschaft mbH Sells 13,204 Shares of Henry Schein, Inc. $HSIC

Universal Beteiligungs und Servicegesellschaft mbH lowered its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 28.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 34,020 shares of the company’s stock after selling 13,204 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Henry Schein were worth $2,589,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Henry Schein by 15.1% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 33,556 shares of the company’s stock valued at $2,536,000 after acquiring an additional 4,390 shares during the last quarter. Berger Financial Group Inc boosted its position in Henry Schein by 6.2% during the fourth quarter. Berger Financial Group Inc now owns 47,720 shares of the company’s stock valued at $3,607,000 after acquiring an additional 2,801 shares during the last quarter. GHP Investment Advisors Inc. boosted its position in Henry Schein by 0.6% during the fourth quarter. GHP Investment Advisors Inc. now owns 52,754 shares of the company’s stock valued at $3,987,000 after acquiring an additional 305 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Henry Schein by 14.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,245 shares of the company’s stock valued at $1,303,000 after acquiring an additional 2,203 shares during the last quarter. Finally, Steph & Co. bought a new stake in Henry Schein during the fourth quarter valued at $52,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $74.59 on Friday. The firm’s 50-day moving average price is $76.59 and its 200-day moving average price is $74.68. Henry Schein, Inc. has a 1-year low of $61.94 and a 1-year high of $89.29. The firm has a market capitalization of $8.56 billion, a P/E ratio of 22.81, a P/E/G ratio of 2.18 and a beta of 0.88. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the prior year, the business earned $1.19 earnings per share. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts anticipate that Henry Schein, Inc. will post 5.3 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the transaction, the director owned 15,420 shares in the company, valued at approximately $1,217,563.20. This represents a 15.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Philip A. Laskawy sold 2,844 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the sale, the director owned 21,961 shares in the company, valued at $1,764,785.96. This represents a 11.47% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 105,911 shares of company stock valued at $8,574,982. Corporate insiders own 0.89% of the company’s stock.

Analyst Upgrades and Downgrades

HSIC has been the topic of a number of research analyst reports. Robert W. Baird set a $100.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research report on Monday, February 23rd. Barrington Research set a $97.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Morgan Stanley reaffirmed an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. JPMorgan Chase & Co. upped their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen lowered shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $87.75.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.